Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Healthcare Copper
Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Medivolve Inc > More good news...$$$
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Post by GeneralWolfeon Apr 08, 2022 9:48am
253 Views
Post# 34587472

More good news...$$$

More good news...$$$Medivolve webinar : Confirmed 200-300mil revenue for 2022, Q4 2021 had $55 mil recievables, significant collection of recievables has occurred with expectation of a max $1.6 mil deduction for bad recievables. Q1 2022 is 'good' comparative to Q4 2021 $180 per patient at the moment. Average revenue per patient per year $1-$2k. (Cross reference to medivolve database of patients they’d have in theory over $1B in recurring revenue) Closest timeline for Telehealth is 3 months for beta test (maybe) and 6 months for commercial. David Preiner is CEO to develop a telehealth business, not to manage a bunch of testing sites. Management believes the stock is significantly undervalued, but can't do anything (considering a share buyback, not a confirmation). New hire Vincent will be handling PR from now on....$$$$$, get in while its dirt cheap...
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities